Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2014-005681-29Phase 2Terminated
Phase 2, randomised, open-label trial of capecitabine and FOLFIRINOX in pancreatic cancer (PC) (2 arms), sponsored by Institut de Cancérologie de Lorraine. Primary endpoint: Histological R0 resection rate. Started Jul 2015; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2014-005681-29.